Thomas Selby, MD
Dermatology · Evansville, INNPI 1679911382
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,644 of the $15,095 with a category attached, or 63.9%. 32 manufacturers reported payments, led by Boehringer Ingelheim at 34.1% of the total.
Across 382 payments — averaging $39.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$5K
- AbbVie$2K
- Lilly USA, LLC$1K
- Johnson & Johnson$939
- Regeneron Healthcare Solutions, Inc.$803
- Galderma Laboratories, L.p.$686
- plus $4K from 26 others
What the payments were for
- Consulting fees$2,98020%
- Speaking & faculty fees$1,91413%
- Food & beverage$9,64464%
- Education$5584%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 11 | $5,153 |
| AbbVie | 70 | $1,814 |
| Lilly USA, LLC | 39 | $1,430 |
| Johnson & Johnson | 36 | $939 |
| Regeneron Healthcare Solutions, Inc. | 27 | $803 |
| Galderma Laboratories, L.p. | 28 | $686 |
| Sun Pharmaceutical Industries Inc. | 17 | $650 |
| Novartis | 26 | $423 |
| E.r. Squibb & Sons, L.L.C. | 19 | $413 |
| Incyte Corporation | 7 | $412 |
| Sanofi | 14 | $384 |
| UCB, Inc. | 17 | $360 |
| Janssen Scientific Affairs, LLC | 5 | $321 |
| LEO Pharma Inc. | 10 | $266 |
| Arcutis Biotherapeutics, Inc. | 11 | $172 |
| Pfizer | 10 | $153 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 9 | $141 |
| Biofrontera Inc. | 3 | $123 |
| Amgen | 6 | $103 |
| Genentech USA, Inc. | 1 | $83 |
| AstraZeneca | 3 | $41 |
| Verrica Pharmaceuticals Inc. | 2 | $39 |
| Organogenesis Inc. | 1 | $28 |
| Organon | 2 | $27 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Botanix SB Inc | 1 | $21 |
| GE HealthCare | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Dermavant Sciences, Inc. | 1 | $15 |
| Krystal Biotech Inc | 1 | $15 |
| Reprise Biomedical, Inc. | 1 | $12 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,095 in reported general payments places this provider in the 85th percentile of 202 dermatology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready (2 Pens)Secukinumab | 18 | $214,223 |
| OtezlaApremilast | 24 | $104,689 |
| ErivedgeVismodegib | 14 | $88,539 |
| Taltz AutoinjectorIxekizumab | 11 | $71,940 |
| Dupixent PenDupilumab | 18 | $66,783 |
| ZoryveRoflumilast | 11 | $9,396 |
| Tacrolimus | 30 | $4,717 |
| Fluorouracil | 64 | $4,358 |
| Clobetasol Propionate | 119 | $3,422 |
| Ketoconazole | 234 | $3,412 |
| Calcipotriene | 19 | $2,770 |
| Fluocinonide | 48 | $2,138 |
| Clindamycin Phosphate | 30 | $1,603 |
| Doxycycline Hyclate | 140 | $1,267 |
| Triamcinolone Acetonide | 124 | $775 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $103 | $104,68924 claims |
| Genentech USA, Inc.Erivedge | $83 | $88,53914 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $172 | $9,39611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 202 dermatology providers in Indiana.
Other dermatology in Evansville
- Charles HudsonEvansville$92K
- Celine MestelEvansville$11K
- Jamie MullEvansville$10K
- Karl StaserEvansville$9K
- Dylan GreeneyEvansville$8K
- Scott GuenthnerPlainfield$1.6M
- David RosmarinIndianapolis$1.1M
- Christopher ObeimeIndianapolis$907K
- Scott FretzinIndianapolis$794K
- Priya YoungIndianapolis$492K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.